Ikarian Capital, LLC Biomea Fusion, Inc. Call Options Transaction History

Ikarian Capital, LLC

4 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2024 May 15, 2024	BUY	$13.92 - $19.5 $4.18 Million - $5.85 Million	300,000 Added 38.58%	1,077,600 $16.1 Million
Q4 2023 Feb 14, 2024	BUY	$8.37 - $19.8 $6.51 Million - $15.4 Million	777,600 New	777,600 $11.3 Million
Q2 2023 Aug 14, 2023	BUY	$21.66 - $41.8 $14 Million - $27 Million	645,800 Added 221.92%	936,800 $20.6 Million
Q1 2023 May 15, 2023	BUY	$6.8 - $32.35 $1.98 Million - $9.41 Million	291,000 New	291,000 $9.02 Million

22.5M

1.12M

371K

Ticker BMEA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 29,290,600
Market Cap $48.3M
Description
Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in onc...

Get notified when there are updates to the investment portfolio of Ikarian Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Ikarian Capital, LLC with notifications on news.